Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, mRNA), Type (Multivalent, Monovalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, Rotavirus, RSV, HPV, Polio), ROA (IM, SC, Oral), Competition - Global Forecast to 2031
The vaccines market (excluding COVID-19) is expected to reach USD 71.14 billion in 2031, up from USD 55.68 billion in 2026, growing at a CAGR of 5.0% during the forecast period. Factors such as the high incidence of contagious diseases, innovation in vaccine technology, government support and substantial funding for vaccine development, increasing vaccination initiatives, and a strong focus on investing in and launching innovative products are driving this growth in vaccines.
By disease indication, the pneumococcal segment accounted for the largest share of the vaccines market in 2025.
Based on disease indication, the vaccines market is segmented into combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, COVID-19, and other disease indications. In 2025, the pneumococcal segment held the largest share of the vaccines market. This is due to several key factors: a rising incidence of pneumococcal infections worldwide; increased government funding for vaccination programs; and heightened public awareness of the serious health risks associated with pneumococcal-related complications such as pneumonia, meningitis, and bloodstream infections. Additionally, ongoing innovation and the development of next-generation pneumococcal vaccines, such as the recently approved 20-valent and 21-valent conjugate vaccines, are expanding immunization options, further boosting market growth and public health benefits.
By type, the multivalent vaccines segment accounted for the largest share of the vaccines market in 2025.
The vaccines market is divided into monovalent vaccines and multivalent vaccines, based on type. In 2025, the multivalent vaccines segment held the largest portion of the Vaccines market. This dominance stems from multivalent vaccines' ability to protect against multiple diseases with a single dose—simplifying immunization by reducing the number of injections needed, which increases patient compliance and decreases logistical challenges. Additionally, the growing prevalence of diseases that require broad-spectrum immunity, such as respiratory infections and certain cancers, has increased demand for these vaccines. Further supporting this trend are technological advances and increased investment in efficient manufacturing of multivalent vaccines, enabling larger and faster production. Governments and healthcare providers in regions with limited healthcare access particularly favor them because simplified vaccination schedules improve coverage and boost public health outcomes.
The Asia Pacific region is expected to grow at the highest CAGR in the vaccines market from 2026 to 2031.
The vaccines market region is divided into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to grow at a significant CAGR during the forecast period. This increase is driven by greater public health awareness, expanding national immunization programs, and increased government investment in healthcare infrastructure. Supporting these efforts are public–private partnerships, international collaborations aimed at improving vaccine equity, and technological advancements that enable advanced vaccine development and more affordable production. Additionally, the region’s large and growing populations, especially in countries such as China and India, present a substantial target market for both established and new vaccines. These factors highlight the Asia Pacific’s leadership in the vaccine industry market.
The primary interviews conducted for this report can be categorized as follows:
Research Coverage
This research report categorizes the vaccines market by technology (conjugate vaccines, recombinant vaccines, inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, and other vaccines), type (monovalent vaccines and multivalent vaccines), indication (pneumococcal disease, influenza, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSV, COVID-19, and other disease indications), route of administration (intramuscular & subcutaneous administration, oral administration, and other routes of administration), end user (pediatric vaccines and adult vaccines), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa).
The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the vaccines market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, product portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments related to the vaccines market. This report includes a competitive analysis of top players and upcoming startups within the vaccines market ecosystem. The report also details primary factors like drivers, restraints, challenges, and opportunities shaping the market growth, along with an in-depth review of key industry players’ solutions, products, recent product launches, mergers, acquisitions, and emerging market trends ecosystem.
Key Benefits of Buying the Report
This report offers a comprehensive overview of the vaccines market. It aims to assess the size and future growth opportunities of the market across various segments, such as technology, type, indication, route of administration, end user, and region. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies.
The report provides insights into the following pointers:
Analysis of key drivers (focus on vaccine development and launches, rising prevalence of infectious diseases, increasing immunization programs, advancements in vaccine technology, and government support & funding for vaccine development), restraints (high cost of vaccine development), opportunities (rising focus on therapeutic vaccines, extensive R&D for vaccines, and increased investments in clinical trials), and challenges (stringent regulatory processes and product recalls)
The report also helps stakeholders understand the trends of the vaccines market and provides information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of key industry players has been conducted to offer insights into their key strategies, product launches and approvals, pipeline developments, acquisitions, partnerships, collaborations, recent activities, investments and funding, brand and product comparisons, vendor evaluations, and financial metrics of the vaccines market.
By disease indication, the pneumococcal segment accounted for the largest share of the vaccines market in 2025.
Based on disease indication, the vaccines market is segmented into combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, COVID-19, and other disease indications. In 2025, the pneumococcal segment held the largest share of the vaccines market. This is due to several key factors: a rising incidence of pneumococcal infections worldwide; increased government funding for vaccination programs; and heightened public awareness of the serious health risks associated with pneumococcal-related complications such as pneumonia, meningitis, and bloodstream infections. Additionally, ongoing innovation and the development of next-generation pneumococcal vaccines, such as the recently approved 20-valent and 21-valent conjugate vaccines, are expanding immunization options, further boosting market growth and public health benefits.
By type, the multivalent vaccines segment accounted for the largest share of the vaccines market in 2025.
The vaccines market is divided into monovalent vaccines and multivalent vaccines, based on type. In 2025, the multivalent vaccines segment held the largest portion of the Vaccines market. This dominance stems from multivalent vaccines' ability to protect against multiple diseases with a single dose—simplifying immunization by reducing the number of injections needed, which increases patient compliance and decreases logistical challenges. Additionally, the growing prevalence of diseases that require broad-spectrum immunity, such as respiratory infections and certain cancers, has increased demand for these vaccines. Further supporting this trend are technological advances and increased investment in efficient manufacturing of multivalent vaccines, enabling larger and faster production. Governments and healthcare providers in regions with limited healthcare access particularly favor them because simplified vaccination schedules improve coverage and boost public health outcomes.
The Asia Pacific region is expected to grow at the highest CAGR in the vaccines market from 2026 to 2031.
The vaccines market region is divided into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to grow at a significant CAGR during the forecast period. This increase is driven by greater public health awareness, expanding national immunization programs, and increased government investment in healthcare infrastructure. Supporting these efforts are public–private partnerships, international collaborations aimed at improving vaccine equity, and technological advancements that enable advanced vaccine development and more affordable production. Additionally, the region’s large and growing populations, especially in countries such as China and India, present a substantial target market for both established and new vaccines. These factors highlight the Asia Pacific’s leadership in the vaccine industry market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side (80%) and Demand Side (20%)
- By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%)
- By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)
Research Coverage
This research report categorizes the vaccines market by technology (conjugate vaccines, recombinant vaccines, inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, and other vaccines), type (monovalent vaccines and multivalent vaccines), indication (pneumococcal disease, influenza, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSV, COVID-19, and other disease indications), route of administration (intramuscular & subcutaneous administration, oral administration, and other routes of administration), end user (pediatric vaccines and adult vaccines), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa).
The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the vaccines market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, product portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments related to the vaccines market. This report includes a competitive analysis of top players and upcoming startups within the vaccines market ecosystem. The report also details primary factors like drivers, restraints, challenges, and opportunities shaping the market growth, along with an in-depth review of key industry players’ solutions, products, recent product launches, mergers, acquisitions, and emerging market trends ecosystem.
Key Benefits of Buying the Report
This report offers a comprehensive overview of the vaccines market. It aims to assess the size and future growth opportunities of the market across various segments, such as technology, type, indication, route of administration, end user, and region. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies.
The report provides insights into the following pointers:
Analysis of key drivers (focus on vaccine development and launches, rising prevalence of infectious diseases, increasing immunization programs, advancements in vaccine technology, and government support & funding for vaccine development), restraints (high cost of vaccine development), opportunities (rising focus on therapeutic vaccines, extensive R&D for vaccines, and increased investments in clinical trials), and challenges (stringent regulatory processes and product recalls)
- Product Development/Innovation: Detailed insights on newly launched products and technological assessment of the vaccines market.
- Market Development: Comprehensive information about lucrative markets; the report analyzes the vaccines market across varied regions.
- Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the vaccines market
The report also helps stakeholders understand the trends of the vaccines market and provides information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of key industry players has been conducted to offer insights into their key strategies, product launches and approvals, pipeline developments, acquisitions, partnerships, collaborations, recent activities, investments and funding, brand and product comparisons, vendor evaluations, and financial metrics of the vaccines market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN VACCINES MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 VACCINES MARKET OVERVIEW
3.2 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE AND COUNTRY, 2025
3.3 VACCINES MARKET (EXCLUDING COVID-19 VACCINES): GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 VACCINES MARKET (EXCLUDING COVID-19 VACCINES) SHARE, BY ROUTE OF ADMINISTRATION, 2026 VS 2031 (%)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Focus on vaccine development and launches
4.2.1.2 Rising prevalence of infectious diseases
4.2.1.3 Increasing immunization programs
4.2.1.4 Advancements in vaccine technology
4.2.1.5 Government support and funding for vaccine development
4.2.2 RESTRAINTS
4.2.2.1 High cost of vaccine development
4.2.3 OPPORTUNITIES
4.2.3.1 Rising focus on therapeutic vaccines
4.2.3.2 Extensive R&D for vaccines and increased investments in clinical trials
4.2.4 CHALLENGES
4.2.4.1 Stringent regulatory processes
4.2.4.2 Product recalls
4.3 UNMET NEEDS & WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL VACCINES INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 PIPELINE ANALYSIS
5.4.1 VACCINES MARKET: CLINICAL TRIALS, BY PHASE
5.4.2 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION
5.4.3 VACCINES MARKET: PHASE 2/3 CLINICAL TRIALS, BY COMPANY
5.5 ECOSYSTEM ANALYSIS
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2024–2026
5.6.2 AVERAGE SELLING PRICE TREND, BY DISEASE INDICATION, 2024–2026
5.6.3 AVERAGE SELLING PRICE TREND, BY REGION, 2022–2024
5.7 TRADE ANALYSIS
5.7.1 IMPORT SCENARIO (HS CODE 300220)
5.7.2 EXPORT SCENARIO (HS CODE 300220)
5.8 KEY CONFERENCES AND EVENTS, 2026–2027
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS
5.10 INVESTMENT AND FUNDING SCENARIO
5.10.1 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
5.11 IMPACT OF 2025 US TARIFFS—VACCINES MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON COUNTRIES/REGIONS
5.11.4.1 US
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 Public health & government bodies
5.11.5.2 Healthcare providers & institutions
5.12 VACCINE PROCUREMENT DATA
5.12.1 NUMBER OF VACCINES DELIVERED BY UNICEF, 2024–2026
5.12.2 WHO: VACCINE PURCHASE DATABASE, 2022–2024
5.13 VACCINE MANUFACTURING PROCESS
5.13.1 OVERVIEW
5.13.1.1 R&D and process development
5.13.1.2 Upstream production (antigen generation)
5.13.1.3 Downstream processing
5.13.1.4 Formulation & fill-finish
5.13.1.5 Quality control & regulatory release
5.13.1.6 Packaging, cold chain, and distribution
5.13.2 MANUFACTURING MODELS & CAPACITY DYNAMICS
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS
6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY EMERGING TECHNOLOGIES
6.1.1.1 Recombinant technology
6.1.1.2 Conjugation technology
6.1.1.3 Viral vector technology
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Encapsulation & delivery technology
6.1.2.2 Automation & control
6.1.2.3 AI & machine learning for vaccine design
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 Single-use technology
6.1.3.2 Cell line development
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.3 PATENT ANALYSIS
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR VACCINE PATENTS
6.4 FUTURE APPLICATIONS
6.5 IMPACT OF AI/GEN AI—VACCINES MARKET
6.5.1 BEST PRACTICES IN VACCINES WORKFLOW
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN VACCINES MARKET
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN VACCINES MARKET
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 REGULATORY FRAMEWORK
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia Pacific
7.1.2.4 Latin America
7.1.2.5 Middle East & Africa
7.1.3 REGULATORY CHALLENGES IN VACCINES MARKET
7.1.4 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA, BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY
9 VACCINES MARKET, BY DISEASE INDICATION
9.1 INTRODUCTION
9.2 PNEUMOCOCCAL DISEASE
9.2.1 EXPANDING ADULT IMMUNIZATION PROGRAMS AND HIGHER-VALENCY VACCINES TO DRIVE MARKET
9.3 INFLUENZA
9.3.1 SEASONAL IMMUNIZATION PROGRAMS AND EXPANDING ADULT VACCINATION TO DRIVE MARKET
9.4 HPV
9.4.1 EXPANDING NATIONAL HPV IMMUNIZATION PROGRAMS AND RISING ADOPTION OF GENDER-NEUTRAL VACCINATION TO DRIVE THE FASTEST-GROWING SEGMENT
9.5 HERPES ZOSTER
9.5.1 RISING AGING POPULATION TO DRIVE DEMAND FOR HERPES ZOSTER VACCINES
9.6 COMBINATION VACCINES
9.6.1 EXPANDING NATIONAL IMMUNIZATION PROGRAMS AND GROWING PREFERENCE FOR MULTI-ANTIGEN VACCINES TO DRIVE MARKET
9.7 MENINGOCOCCAL DISEASE
9.7.1 EXPANDING IMMUNIZATION RECOMMENDATIONS AND BROADER SEROGROUP COVERAGE TO SUPPORT MARKET GROWTH
9.8 ROTAVIRUS
9.8.1 RISING INFANT IMMUNIZATION PROGRAMS TO DRIVE ROTAVIRUS MARKET GROWTH
9.9 RSV
9.9.1 INITIAL VACCINE UPTAKE AND EXPANDING IMMUNIZATION RECOMMENDATIONS SUPPORT MARKET PENETRATION
9.10 DTP
9.10.1 CONTINUED ROUTINE CHILDHOOD IMMUNIZATION AND BOOSTER VACCINATION PROGRAMS TO SUPPORT MARKET
9.11 HEPATITIS
9.11.1 EXPANDING HEPATITIS B IMMUNIZATION AND GLOBAL ELIMINATION INITIATIVES TO SUPPORT MARKET GROWTH
9.12 VARICELLA
9.12.1 EXPANDING CHILDHOOD IMMUNIZATION PROGRAMS AND INCREASING ADOPTION OF VARICELLA VACCINES TO SUPPORT MARKET GROWTH
9.13 MMR
9.13.1 RISING MEASLES OUTBREAKS AND IMMUNIZATION RECOVERY EFFORTS TO SUPPORT MARKET GROWTH
9.14 POLIO
9.14.1 GLOBAL POLIO ERADICATION INITIATIVES AND CONTINUED VACCINATION CAMPAIGNS TO SUSTAIN MARKET DEMAND
9.15 COVID-19
9.15.1 SHIFT FROM PANDEMIC-DRIVEN DEMAND TO ENDURING HIGH-RISK POPULATION VACCINATION, RESULTING IN MARKET NORMALIZATION
9.16 OTHER DISEASE INDICATIONS
10 VACCINES MARKET, BY TECHNOLOGY
10.1 INTRODUCTION
10.2 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY
10.2.1 RECOMBINANT VACCINES
10.2.1.1 Broader adult immunization and continued recombinant vaccine launches to drive market
10.2.2 CONJUGATE VACCINES
10.2.2.1 Higher-valency pneumococcal vaccines and large public immunization programs to drive market
10.2.3 INACTIVATED & SUBUNIT VACCINES
10.2.3.1 Recurring influenza demand and wider access to established non-live vaccines to support market
10.2.4 LIVE ATTENUATED VACCINES
10.2.4.1 Durable immune protection and convenient oral or nasal administration to support market
10.2.5 TOXOID VACCINES
10.2.5.1 Routine pediatric boosters and maternal immunization programs to sustain market
10.2.6 OTHER VACCINES
10.3 COVID-19 VACCINES MARKET, BY TECHNOLOGY
10.3.1 MRNA VACCINES
10.3.1.1 Rapid variant adaptation and continued vaccination of high-risk populations to drive market
10.3.2 VIRAL VECTOR VACCINES
10.3.2.1 Withdrawal of first-generation products and shift toward updated vaccine platforms to accelerate market decline
10.3.3 OTHER COVID-19 VACCINES
11 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE
11.1 INTRODUCTION
11.2 MULTIVALENT VACCINES
11.2.1 BROADER SEROTYPE COVERAGE AND INCREASING ADOPTION OF COMBINATION IMMUNIZATION SCHEDULES TO DRIVE MARKET
11.3 MONOVALENT VACCINES
11.3.1 ESTABLISHED SINGLE-DISEASE PROGRAMS AND EXPANDING ADULT IMMUNIZATION INDICATIONS TO SUPPORT MARKET
12 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION
12.1 INTRODUCTION
12.2 INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION
12.2.1 EASE OF ABSORPTION AND BETTER IMMUNE RESPONSE TO DRIVE ADOPTION
12.3 ORAL ADMINISTRATION
12.3.1 NEEDLE-FREE DELIVERY AND HIGH-VOLUME DISEASE-CONTROL CAMPAIGNS TO SUPPORT MARKET
12.4 OTHER ROUTES OF ADMINISTRATION
13 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER
13.1 INTRODUCTION
13.2 ADULT VACCINES
13.2.1 AGING POPULATIONS, BROADER ADULT INDICATIONS, AND GROWING LIFE-COURSE IMMUNIZATION TO DRIVE MARKET
13.3 PEDIATRIC VACCINES
13.3.1 EXPANDING CHILDHOOD IMMUNIZATION SCHEDULES AND NEW VACCINE INTRODUCTIONS TO DRIVE MARKET GROWTH
14 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 US
14.2.1.1 US to dominate North American market during forecast period
14.2.2 CANADA
14.2.2.1 Expansion of life-course immunization to support market growth
14.3 EUROPE
14.3.1 GERMANY
14.3.1.1 Adult immunization and updated national recommendations to drive market growth
14.3.2 UK
14.3.2.1 Expansion of adult and maternal immunization programs to support market growth
14.3.3 FRANCE
14.3.3.1 Favorable government initiatives for mass immunization to drive market
14.3.4 ITALY
14.3.4.1 Higher investments by companies for increased production capacities to drive market
14.3.5 SPAIN
14.3.5.1 Rising investments in vaccine development by private organizations to drive market
14.3.6 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 CHINA
14.4.1.1 China to hold largest share of APAC vaccines market
14.4.2 JAPAN
14.4.2.1 Aging population and gradual expansion of routine vaccination to drive demand
14.4.3 INDIA
14.4.3.1 Large immunization requirements and manufacturing leadership to support strong growth
14.4.4 SOUTH KOREA
14.4.4.1 Strong government strategies for improved vaccine hubs to drive market
14.4.5 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 BRAZIL
14.5.1.1 Strong public procurement and domestic manufacturing to drive market
14.5.2 MEXICO
14.5.2.1 Trained workforce and ethnically varied population base for clinical trials to propel market growth
14.5.3 REST OF LATIN AMERICA
14.6 MIDDLE EAST
14.6.1 GOVERNMENT-LED LOCALIZATION AND EXPANDING ADULT AND TRAVEL IMMUNIZATION TO SUPPORT MARKET GROWTH
14.7 AFRICA
14.7.1 HIGH UNMET IMMUNIZATION NEEDS AND LOCAL MANUFACTURING INITIATIVES TO DRIVE MARKET EXPANSION
15 COMPETITIVE LANDSCAPE
15.1 OVERVIEW
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN VACCINES MARKET
15.3 REVENUE ANALYSIS, 2021–2025
15.4 MARKET SHARE ANALYSIS, 2025
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1 Company footprint
15.5.5.2 Region footprint
15.5.5.3 Technology footprint
15.5.5.4 Type footprint
15.5.5.5 Route of administration footprint
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
15.6.5.1 Detailed list of key startups/SMEs
15.6.5.2 Competitive benchmarking of key startups/SMEs
15.7 COMPANY VALUATION & FINANCIAL METRICS
15.7.1 FINANCIAL METRICS
15.7.2 COMPANY VALUATION
15.8 PRODUCT COMPARISON
15.8.1 PRODUCT COMPARATIVE ANALYSIS
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT LAUNCHES & APPROVALS
15.9.2 DEALS
15.9.3 EXPANSIONS
16 COMPANY PROFILES
16.1 KEY PLAYERS
16.1.1 PFIZER INC.
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product approvals
16.1.1.4 MnM view
16.1.1.4.1 Key strengths
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses & competitive threats
16.1.2 GSK PLC
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches & approvals
16.1.2.3.2 Deals
16.1.2.3.3 Expansions
16.1.2.4 MnM view
16.1.2.4.1 Key strengths
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses & competitive threats
16.1.3 MERCK & CO., INC.
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product approvals
16.1.3.3.2 Expansions
16.1.3.4 MnM view
16.1.3.4.1 Key strengths
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses & competitive threats
16.1.4 SANOFI
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Product approvals
16.1.4.3.2 Deals
16.1.4.3.3 Expansions
16.1.4.3.4 Other developments
16.1.4.4 MnM view
16.1.4.4.1 Key strengths
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses & competitive threats
16.1.5 CSL
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 Recent developments
16.1.5.3.1 Product approvals
16.1.5.3.2 Deals
16.1.5.3.3 Expansions
16.1.6 EMERGENT
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Recent developments
16.1.6.3.1 Product approvals
16.1.6.3.2 Deals
16.1.6.3.3 Other developments
16.1.7 JOHNSON & JOHNSON SERVICES, INC.
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.7.3 Recent developments
16.1.7.3.1 Deals
16.1.8 ASTRAZENECA
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Deals
16.1.8.3.2 Expansions
16.1.9 SERUM INSTITUTE OF INDIA PVT. LTD.
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Recent developments
16.1.9.3.1 Product launches & approvals
16.1.9.3.2 Deals
16.1.9.3.3 Expansions
16.1.10 BAVARIAN NORDIC
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Recent developments
16.1.10.3.1 Product approvals
16.1.10.3.2 Deals
16.1.10.3.3 Other developments
16.1.11 TANABE PHARMA CORPORATION
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Product launches & approvals
16.1.11.3.2 Deals
16.1.12 DAIICHI SANKYO COMPANY, LIMITED
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.12.3 Recent developments
16.1.12.3.1 Deals
16.1.13 PANACEA BIOTEC
16.1.13.1 Business overview
16.1.13.2 Products offered
16.1.13.3 Recent developments
16.1.13.3.1 Other developments
16.1.14 BIOLOGICAL E. LIMITED
16.1.14.1 Business overview
16.1.14.2 Products offered
16.1.14.3 Recent developments
16.1.14.3.1 Product approvals
16.1.14.3.2 Deals
16.1.14.3.3 Other developments
16.1.15 BHARAT BIOTECH
16.1.15.1 Business overview
16.1.15.2 Products offered
16.1.15.3 Recent developments
16.1.15.3.1 Product launches & approvals
16.1.15.3.2 Deals
16.1.16 NOVAVAX
16.1.16.1 Business overview
16.1.16.2 Products offered
16.1.16.3 Recent developments
16.1.16.3.1 Product approvals
16.1.16.3.2 Deals
16.1.17 INOVIO PHARMACEUTICALS
16.1.17.1 Business overview
16.1.17.2 Products offered
16.1.17.3 Recent developments
16.1.17.3.1 Other developments
16.2 OTHER PLAYERS
16.2.1 SINOVAC
16.2.2 INCEPTA PHARMACEUTICALS LTD.
16.2.3 VALNEVA SE
16.2.4 EUBIOLOGICS CO., LTD.
16.2.5 BIO FARMA
16.2.6 MICROGEN
16.2.7 CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
16.2.8 INDIAN IMMUNOLOGICALS LIMITED
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.1.1 SECONDARY DATA
17.1.1.1 Key secondary sources
17.1.1.2 Key data from secondary research
17.1.2 PRIMARY DATA
17.1.2.1 Key primary participants
17.1.2.2 Breakdown of primary interviews
17.1.2.3 Key data from primary sources
17.2 MARKET SIZE ESTIMATION
17.2.1 GLOBAL VACCINES MARKET SIZE ESTIMATION, 2025
17.2.1.1 Approach 1: Company revenue analysis-based estimation (bottom-up approach)
17.2.1.2 Approach 2: Primary research
17.2.1.2.1 Key industry insights
17.2.1.3 Approach 3: Secondary analysis
17.2.1.4 Approach 4: Bottom-up approach (disease indication-based analysis)
17.2.1.5 Approach 5: MarketsandMarkets repository analysis
17.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH), 2025
17.3 MARKET GROWTH RATE PROJECTIONS
17.4 DATA TRIANGULATION
17.5 RESEARCH ASSUMPTIONS
17.6 RESEARCH LIMITATIONS & RISK ASSESSMENT
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN VACCINES MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 VACCINES MARKET OVERVIEW
3.2 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE AND COUNTRY, 2025
3.3 VACCINES MARKET (EXCLUDING COVID-19 VACCINES): GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 VACCINES MARKET (EXCLUDING COVID-19 VACCINES) SHARE, BY ROUTE OF ADMINISTRATION, 2026 VS 2031 (%)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Focus on vaccine development and launches
4.2.1.2 Rising prevalence of infectious diseases
4.2.1.3 Increasing immunization programs
4.2.1.4 Advancements in vaccine technology
4.2.1.5 Government support and funding for vaccine development
4.2.2 RESTRAINTS
4.2.2.1 High cost of vaccine development
4.2.3 OPPORTUNITIES
4.2.3.1 Rising focus on therapeutic vaccines
4.2.3.2 Extensive R&D for vaccines and increased investments in clinical trials
4.2.4 CHALLENGES
4.2.4.1 Stringent regulatory processes
4.2.4.2 Product recalls
4.3 UNMET NEEDS & WHITE SPACES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL VACCINES INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 PIPELINE ANALYSIS
5.4.1 VACCINES MARKET: CLINICAL TRIALS, BY PHASE
5.4.2 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION
5.4.3 VACCINES MARKET: PHASE 2/3 CLINICAL TRIALS, BY COMPANY
5.5 ECOSYSTEM ANALYSIS
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2024–2026
5.6.2 AVERAGE SELLING PRICE TREND, BY DISEASE INDICATION, 2024–2026
5.6.3 AVERAGE SELLING PRICE TREND, BY REGION, 2022–2024
5.7 TRADE ANALYSIS
5.7.1 IMPORT SCENARIO (HS CODE 300220)
5.7.2 EXPORT SCENARIO (HS CODE 300220)
5.8 KEY CONFERENCES AND EVENTS, 2026–2027
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS
5.10 INVESTMENT AND FUNDING SCENARIO
5.10.1 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
5.11 IMPACT OF 2025 US TARIFFS—VACCINES MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON COUNTRIES/REGIONS
5.11.4.1 US
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 Public health & government bodies
5.11.5.2 Healthcare providers & institutions
5.12 VACCINE PROCUREMENT DATA
5.12.1 NUMBER OF VACCINES DELIVERED BY UNICEF, 2024–2026
5.12.2 WHO: VACCINE PURCHASE DATABASE, 2022–2024
5.13 VACCINE MANUFACTURING PROCESS
5.13.1 OVERVIEW
5.13.1.1 R&D and process development
5.13.1.2 Upstream production (antigen generation)
5.13.1.3 Downstream processing
5.13.1.4 Formulation & fill-finish
5.13.1.5 Quality control & regulatory release
5.13.1.6 Packaging, cold chain, and distribution
5.13.2 MANUFACTURING MODELS & CAPACITY DYNAMICS
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS
6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY EMERGING TECHNOLOGIES
6.1.1.1 Recombinant technology
6.1.1.2 Conjugation technology
6.1.1.3 Viral vector technology
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Encapsulation & delivery technology
6.1.2.2 Automation & control
6.1.2.3 AI & machine learning for vaccine design
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 Single-use technology
6.1.3.2 Cell line development
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.3 PATENT ANALYSIS
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR VACCINE PATENTS
6.4 FUTURE APPLICATIONS
6.5 IMPACT OF AI/GEN AI—VACCINES MARKET
6.5.1 BEST PRACTICES IN VACCINES WORKFLOW
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN VACCINES MARKET
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN VACCINES MARKET
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 REGULATORY FRAMEWORK
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia Pacific
7.1.2.4 Latin America
7.1.2.5 Middle East & Africa
7.1.3 REGULATORY CHALLENGES IN VACCINES MARKET
7.1.4 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA, BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY
9 VACCINES MARKET, BY DISEASE INDICATION
9.1 INTRODUCTION
9.2 PNEUMOCOCCAL DISEASE
9.2.1 EXPANDING ADULT IMMUNIZATION PROGRAMS AND HIGHER-VALENCY VACCINES TO DRIVE MARKET
9.3 INFLUENZA
9.3.1 SEASONAL IMMUNIZATION PROGRAMS AND EXPANDING ADULT VACCINATION TO DRIVE MARKET
9.4 HPV
9.4.1 EXPANDING NATIONAL HPV IMMUNIZATION PROGRAMS AND RISING ADOPTION OF GENDER-NEUTRAL VACCINATION TO DRIVE THE FASTEST-GROWING SEGMENT
9.5 HERPES ZOSTER
9.5.1 RISING AGING POPULATION TO DRIVE DEMAND FOR HERPES ZOSTER VACCINES
9.6 COMBINATION VACCINES
9.6.1 EXPANDING NATIONAL IMMUNIZATION PROGRAMS AND GROWING PREFERENCE FOR MULTI-ANTIGEN VACCINES TO DRIVE MARKET
9.7 MENINGOCOCCAL DISEASE
9.7.1 EXPANDING IMMUNIZATION RECOMMENDATIONS AND BROADER SEROGROUP COVERAGE TO SUPPORT MARKET GROWTH
9.8 ROTAVIRUS
9.8.1 RISING INFANT IMMUNIZATION PROGRAMS TO DRIVE ROTAVIRUS MARKET GROWTH
9.9 RSV
9.9.1 INITIAL VACCINE UPTAKE AND EXPANDING IMMUNIZATION RECOMMENDATIONS SUPPORT MARKET PENETRATION
9.10 DTP
9.10.1 CONTINUED ROUTINE CHILDHOOD IMMUNIZATION AND BOOSTER VACCINATION PROGRAMS TO SUPPORT MARKET
9.11 HEPATITIS
9.11.1 EXPANDING HEPATITIS B IMMUNIZATION AND GLOBAL ELIMINATION INITIATIVES TO SUPPORT MARKET GROWTH
9.12 VARICELLA
9.12.1 EXPANDING CHILDHOOD IMMUNIZATION PROGRAMS AND INCREASING ADOPTION OF VARICELLA VACCINES TO SUPPORT MARKET GROWTH
9.13 MMR
9.13.1 RISING MEASLES OUTBREAKS AND IMMUNIZATION RECOVERY EFFORTS TO SUPPORT MARKET GROWTH
9.14 POLIO
9.14.1 GLOBAL POLIO ERADICATION INITIATIVES AND CONTINUED VACCINATION CAMPAIGNS TO SUSTAIN MARKET DEMAND
9.15 COVID-19
9.15.1 SHIFT FROM PANDEMIC-DRIVEN DEMAND TO ENDURING HIGH-RISK POPULATION VACCINATION, RESULTING IN MARKET NORMALIZATION
9.16 OTHER DISEASE INDICATIONS
10 VACCINES MARKET, BY TECHNOLOGY
10.1 INTRODUCTION
10.2 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY
10.2.1 RECOMBINANT VACCINES
10.2.1.1 Broader adult immunization and continued recombinant vaccine launches to drive market
10.2.2 CONJUGATE VACCINES
10.2.2.1 Higher-valency pneumococcal vaccines and large public immunization programs to drive market
10.2.3 INACTIVATED & SUBUNIT VACCINES
10.2.3.1 Recurring influenza demand and wider access to established non-live vaccines to support market
10.2.4 LIVE ATTENUATED VACCINES
10.2.4.1 Durable immune protection and convenient oral or nasal administration to support market
10.2.5 TOXOID VACCINES
10.2.5.1 Routine pediatric boosters and maternal immunization programs to sustain market
10.2.6 OTHER VACCINES
10.3 COVID-19 VACCINES MARKET, BY TECHNOLOGY
10.3.1 MRNA VACCINES
10.3.1.1 Rapid variant adaptation and continued vaccination of high-risk populations to drive market
10.3.2 VIRAL VECTOR VACCINES
10.3.2.1 Withdrawal of first-generation products and shift toward updated vaccine platforms to accelerate market decline
10.3.3 OTHER COVID-19 VACCINES
11 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE
11.1 INTRODUCTION
11.2 MULTIVALENT VACCINES
11.2.1 BROADER SEROTYPE COVERAGE AND INCREASING ADOPTION OF COMBINATION IMMUNIZATION SCHEDULES TO DRIVE MARKET
11.3 MONOVALENT VACCINES
11.3.1 ESTABLISHED SINGLE-DISEASE PROGRAMS AND EXPANDING ADULT IMMUNIZATION INDICATIONS TO SUPPORT MARKET
12 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION
12.1 INTRODUCTION
12.2 INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION
12.2.1 EASE OF ABSORPTION AND BETTER IMMUNE RESPONSE TO DRIVE ADOPTION
12.3 ORAL ADMINISTRATION
12.3.1 NEEDLE-FREE DELIVERY AND HIGH-VOLUME DISEASE-CONTROL CAMPAIGNS TO SUPPORT MARKET
12.4 OTHER ROUTES OF ADMINISTRATION
13 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER
13.1 INTRODUCTION
13.2 ADULT VACCINES
13.2.1 AGING POPULATIONS, BROADER ADULT INDICATIONS, AND GROWING LIFE-COURSE IMMUNIZATION TO DRIVE MARKET
13.3 PEDIATRIC VACCINES
13.3.1 EXPANDING CHILDHOOD IMMUNIZATION SCHEDULES AND NEW VACCINE INTRODUCTIONS TO DRIVE MARKET GROWTH
14 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 US
14.2.1.1 US to dominate North American market during forecast period
14.2.2 CANADA
14.2.2.1 Expansion of life-course immunization to support market growth
14.3 EUROPE
14.3.1 GERMANY
14.3.1.1 Adult immunization and updated national recommendations to drive market growth
14.3.2 UK
14.3.2.1 Expansion of adult and maternal immunization programs to support market growth
14.3.3 FRANCE
14.3.3.1 Favorable government initiatives for mass immunization to drive market
14.3.4 ITALY
14.3.4.1 Higher investments by companies for increased production capacities to drive market
14.3.5 SPAIN
14.3.5.1 Rising investments in vaccine development by private organizations to drive market
14.3.6 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 CHINA
14.4.1.1 China to hold largest share of APAC vaccines market
14.4.2 JAPAN
14.4.2.1 Aging population and gradual expansion of routine vaccination to drive demand
14.4.3 INDIA
14.4.3.1 Large immunization requirements and manufacturing leadership to support strong growth
14.4.4 SOUTH KOREA
14.4.4.1 Strong government strategies for improved vaccine hubs to drive market
14.4.5 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 BRAZIL
14.5.1.1 Strong public procurement and domestic manufacturing to drive market
14.5.2 MEXICO
14.5.2.1 Trained workforce and ethnically varied population base for clinical trials to propel market growth
14.5.3 REST OF LATIN AMERICA
14.6 MIDDLE EAST
14.6.1 GOVERNMENT-LED LOCALIZATION AND EXPANDING ADULT AND TRAVEL IMMUNIZATION TO SUPPORT MARKET GROWTH
14.7 AFRICA
14.7.1 HIGH UNMET IMMUNIZATION NEEDS AND LOCAL MANUFACTURING INITIATIVES TO DRIVE MARKET EXPANSION
15 COMPETITIVE LANDSCAPE
15.1 OVERVIEW
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN VACCINES MARKET
15.3 REVENUE ANALYSIS, 2021–2025
15.4 MARKET SHARE ANALYSIS, 2025
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1 Company footprint
15.5.5.2 Region footprint
15.5.5.3 Technology footprint
15.5.5.4 Type footprint
15.5.5.5 Route of administration footprint
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
15.6.5.1 Detailed list of key startups/SMEs
15.6.5.2 Competitive benchmarking of key startups/SMEs
15.7 COMPANY VALUATION & FINANCIAL METRICS
15.7.1 FINANCIAL METRICS
15.7.2 COMPANY VALUATION
15.8 PRODUCT COMPARISON
15.8.1 PRODUCT COMPARATIVE ANALYSIS
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT LAUNCHES & APPROVALS
15.9.2 DEALS
15.9.3 EXPANSIONS
16 COMPANY PROFILES
16.1 KEY PLAYERS
16.1.1 PFIZER INC.
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product approvals
16.1.1.4 MnM view
16.1.1.4.1 Key strengths
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses & competitive threats
16.1.2 GSK PLC
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches & approvals
16.1.2.3.2 Deals
16.1.2.3.3 Expansions
16.1.2.4 MnM view
16.1.2.4.1 Key strengths
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses & competitive threats
16.1.3 MERCK & CO., INC.
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product approvals
16.1.3.3.2 Expansions
16.1.3.4 MnM view
16.1.3.4.1 Key strengths
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses & competitive threats
16.1.4 SANOFI
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Product approvals
16.1.4.3.2 Deals
16.1.4.3.3 Expansions
16.1.4.3.4 Other developments
16.1.4.4 MnM view
16.1.4.4.1 Key strengths
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses & competitive threats
16.1.5 CSL
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 Recent developments
16.1.5.3.1 Product approvals
16.1.5.3.2 Deals
16.1.5.3.3 Expansions
16.1.6 EMERGENT
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Recent developments
16.1.6.3.1 Product approvals
16.1.6.3.2 Deals
16.1.6.3.3 Other developments
16.1.7 JOHNSON & JOHNSON SERVICES, INC.
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.7.3 Recent developments
16.1.7.3.1 Deals
16.1.8 ASTRAZENECA
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Deals
16.1.8.3.2 Expansions
16.1.9 SERUM INSTITUTE OF INDIA PVT. LTD.
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Recent developments
16.1.9.3.1 Product launches & approvals
16.1.9.3.2 Deals
16.1.9.3.3 Expansions
16.1.10 BAVARIAN NORDIC
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Recent developments
16.1.10.3.1 Product approvals
16.1.10.3.2 Deals
16.1.10.3.3 Other developments
16.1.11 TANABE PHARMA CORPORATION
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Product launches & approvals
16.1.11.3.2 Deals
16.1.12 DAIICHI SANKYO COMPANY, LIMITED
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.12.3 Recent developments
16.1.12.3.1 Deals
16.1.13 PANACEA BIOTEC
16.1.13.1 Business overview
16.1.13.2 Products offered
16.1.13.3 Recent developments
16.1.13.3.1 Other developments
16.1.14 BIOLOGICAL E. LIMITED
16.1.14.1 Business overview
16.1.14.2 Products offered
16.1.14.3 Recent developments
16.1.14.3.1 Product approvals
16.1.14.3.2 Deals
16.1.14.3.3 Other developments
16.1.15 BHARAT BIOTECH
16.1.15.1 Business overview
16.1.15.2 Products offered
16.1.15.3 Recent developments
16.1.15.3.1 Product launches & approvals
16.1.15.3.2 Deals
16.1.16 NOVAVAX
16.1.16.1 Business overview
16.1.16.2 Products offered
16.1.16.3 Recent developments
16.1.16.3.1 Product approvals
16.1.16.3.2 Deals
16.1.17 INOVIO PHARMACEUTICALS
16.1.17.1 Business overview
16.1.17.2 Products offered
16.1.17.3 Recent developments
16.1.17.3.1 Other developments
16.2 OTHER PLAYERS
16.2.1 SINOVAC
16.2.2 INCEPTA PHARMACEUTICALS LTD.
16.2.3 VALNEVA SE
16.2.4 EUBIOLOGICS CO., LTD.
16.2.5 BIO FARMA
16.2.6 MICROGEN
16.2.7 CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
16.2.8 INDIAN IMMUNOLOGICALS LIMITED
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.1.1 SECONDARY DATA
17.1.1.1 Key secondary sources
17.1.1.2 Key data from secondary research
17.1.2 PRIMARY DATA
17.1.2.1 Key primary participants
17.1.2.2 Breakdown of primary interviews
17.1.2.3 Key data from primary sources
17.2 MARKET SIZE ESTIMATION
17.2.1 GLOBAL VACCINES MARKET SIZE ESTIMATION, 2025
17.2.1.1 Approach 1: Company revenue analysis-based estimation (bottom-up approach)
17.2.1.2 Approach 2: Primary research
17.2.1.2.1 Key industry insights
17.2.1.3 Approach 3: Secondary analysis
17.2.1.4 Approach 4: Bottom-up approach (disease indication-based analysis)
17.2.1.5 Approach 5: MarketsandMarkets repository analysis
17.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH), 2025
17.3 MARKET GROWTH RATE PROJECTIONS
17.4 DATA TRIANGULATION
17.5 RESEARCH ASSUMPTIONS
17.6 RESEARCH LIMITATIONS & RISK ASSESSMENT
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 VACCINES MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 VACCINES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 3 NIH FUNDING FOR VACCINE RESEARCH, 2020–2025 (USD MILLION)
TABLE 4 MAJOR COST DRIVERS AND IMPACT ON COST OF GOODS SOLD (COGS)
TABLE 5 NOTABLE CANCER VACCINES IN CLINICAL TRIALS
TABLE 6 VACCINES MARKET: IMPACT OF PORTER’S FIVE FORCES
TABLE 7 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR RSV
TABLE 8 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR CANCER
TABLE 9 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR INFLUENZA
TABLE 10 KEY PIPELINE VACCINES: GSK PLC
TABLE 11 KEY PIPELINE VACCINES: MERCK & CO., INC.
TABLE 12 KEY PIPELINE VACCINES: PFIZER INC.
TABLE 13 KEY PIPELINE VACCINES: SANOFI
TABLE 14 VACCINES MARKET: ROLE IN ECOSYSTEM
TABLE 15 AVERAGE SELLING PRICE TREND OF PEDIATRIC VACCINES, BY KEY PLAYER, 2024–2026 (USD)
TABLE 16 AVERAGE SELLING PRICE TREND OF ADULT VACCINES, BY KEY PLAYER, 2024–2026 (USD)
TABLE 17 AVERAGE SELLING PRICE TREND OF VACCINES, BY REGION, 2022–2024 (USD)
TABLE 18 IMPORT DATA FOR HS CODE 300220, 2021–2025 (USD THOUSAND)
TABLE 19 IMPORT DATA FOR HS CODE 300220, 2021–2025 (TONS)
TABLE 20 EXPORT DATA FOR HS CODE 300220, 2021–2025 (USD THOUSAND)
TABLE 21 EXPORT DATA FOR HS CODE 300220, 2021–2025 (TONS)
TABLE 22 VACCINES MARKET: KEY CONFERENCES AND EVENTS, 2026–2027
TABLE 23 US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 24 NUMBER OF VACCINES DELIVERED BY UNICEF, 2024–2026
TABLE 25 WHO VACCINE PURCHASE DATABASE, BY PROCUREMENT MECHANISM, 2022–2024
TABLE 26 WHO VACCINE PURCHASE DATABASE, BY MANUFACTURER, 2022–2024
TABLE 27 WHO VACCINE PURCHASE DATABASE, BY INDICATION, 2022–2024
TABLE 28 WHO VACCINE PURCHASE DATABASE, BY REGION, 2022–2024
TABLE 29 VACCINE PRODUCTION CAPACITY, BY KEY PLAYER, 2025
TABLE 30 KEY VACCINE MANUFACTURING CAPACITY EXPANSIONS, 2025–2026
TABLE 31 VACCINES MARKET: INDICATIVE LIST OF PATENTS, 2026
TABLE 32 CASE STUDIES OF AI IMPLEMENTATION IN VACCINES MARKET
TABLE 33 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN VACCINES
TABLE 34 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 35 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 36 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 37 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 38 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY VACCINES
TABLE 39 KEY BUYING CRITERIA, BY END USER
TABLE 40 VACCINES MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
TABLE 41 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES
TABLE 42 PNEUMOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 43 NORTH AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 44 EUROPE: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 ASIA PACIFIC: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46 LATIN AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES
TABLE 48 INFLUENZA VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 49 NORTH AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 EUROPE: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51 ASIA PACIFIC: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 LATIN AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES
TABLE 54 HPV VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 55 NORTH AMERICA: HPV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56 EUROPE: HPV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 ASIA PACIFIC: HPV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58 LATIN AMERICA: HPV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 LIST OF COMMERCIALLY AVAILABLE HERPES ZOSTER VACCINES
TABLE 60 HERPES ZOSTER VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 NORTH AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 EUROPE: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 ASIA PACIFIC: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64 LATIN AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES
TABLE 66 COMBINATION VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 67 NORTH AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 EUROPE: COMBINATION VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 69 ASIA PACIFIC: COMBINATION VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 LATIN AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES
TABLE 72 MENINGOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 73 NORTH AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74 EUROPE: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 ASIA PACIFIC: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 LATIN AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES
TABLE 78 ROTAVIRUS VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 79 NORTH AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 EUROPE: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81 ASIA PACIFIC: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 LATIN AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 LIST OF COMMERCIALLY AVAILABLE RSV VACCINES
TABLE 84 RSV VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 85 NORTH AMERICA: RSV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 EUROPE: RSV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87 ASIA PACIFIC: RSV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 LATIN AMERICA: RSV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES
TABLE 90 DTP VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 91 NORTH AMERICA: DTP VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 EUROPE: DTP VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 ASIA PACIFIC: DTP VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 LATIN AMERICA: DTP VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES
TABLE 96 HEPATITIS VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 97 NORTH AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 EUROPE: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 ASIA PACIFIC: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 LATIN AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES
TABLE 102 VARICELLA VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 103 NORTH AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 EUROPE: VARICELLA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105 ASIA PACIFIC: VARICELLA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 LATIN AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 TOP 10 COUNTRIES WITH MEASLES OUTBREAKS, JANUARY 2025–JULY 2025
TABLE 108 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES
TABLE 109 MMR VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 110 NORTH AMERICA: MMR VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 EUROPE: MMR VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112 ASIA PACIFIC: MMR VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 LATIN AMERICA: MMR VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 POLIO VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 115 NORTH AMERICA: POLIO VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116 EUROPE: POLIO VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117 ASIA PACIFIC: POLIO VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 LATIN AMERICA: POLIO VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 COVID-19 VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 120 NORTH AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121 EUROPE: COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 ASIA PACIFIC: COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 LATIN AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS
TABLE 125 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 126 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 127 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 131 EXAMPLES OF RECOMBINANT VACCINES
TABLE 132 RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 133 NORTH AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134 EUROPE: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 ASIA PACIFIC: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 LATIN AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 EXAMPLES OF CONJUGATE VACCINES
TABLE 138 CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 139 NORTH AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140 EUROPE: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 ASIA PACIFIC: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142 LATIN AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES
TABLE 144 INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 145 NORTH AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 EUROPE: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147 ASIA PACIFIC: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 LATIN AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 149 EXAMPLES OF LIVE ATTENUATED VACCINES
TABLE 150 LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 151 NORTH AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 EUROPE: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 ASIA PACIFIC: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154 LATIN AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 EXAMPLES OF TOXOID VACCINES
TABLE 156 TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 157 NORTH AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158 EUROPE: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159 ASIA PACIFIC: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160 LATIN AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 162 NORTH AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 163 EUROPE: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 ASIA PACIFIC: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 LATIN AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 COVID-19 VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 167 MRNA COVID-19 VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 168 NORTH AMERICA: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 EUROPE: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 ASIA PACIFIC: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 171 LATIN AMERICA: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 VIRAL VECTOR COVID-19 VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 173 NORTH AMERICA: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174 EUROPE: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 ASIA PACIFIC: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 LATIN AMERICA: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 OTHER COVID-19 VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 178 NORTH AMERICA: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179 EUROPE: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 180 ASIA PACIFIC: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 LATIN AMERICA: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION)
TABLE 183 EXAMPLES OF MULTIVALENT VACCINES
TABLE 184 MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 185 NORTH AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 EUROPE: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 ASIA PACIFIC: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 LATIN AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 EXAMPLES OF MONOVALENT VACCINES
TABLE 190 MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 191 NORTH AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 192 EUROPE: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 ASIA PACIFIC: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 LATIN AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 196 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION
TABLE 197 VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 198 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 203 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 208 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION)
TABLE 213 ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 214 NORTH AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 215 EUROPE: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 1 VACCINES MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 VACCINES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 3 NIH FUNDING FOR VACCINE RESEARCH, 2020–2025 (USD MILLION)
TABLE 4 MAJOR COST DRIVERS AND IMPACT ON COST OF GOODS SOLD (COGS)
TABLE 5 NOTABLE CANCER VACCINES IN CLINICAL TRIALS
TABLE 6 VACCINES MARKET: IMPACT OF PORTER’S FIVE FORCES
TABLE 7 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR RSV
TABLE 8 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR CANCER
TABLE 9 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR INFLUENZA
TABLE 10 KEY PIPELINE VACCINES: GSK PLC
TABLE 11 KEY PIPELINE VACCINES: MERCK & CO., INC.
TABLE 12 KEY PIPELINE VACCINES: PFIZER INC.
TABLE 13 KEY PIPELINE VACCINES: SANOFI
TABLE 14 VACCINES MARKET: ROLE IN ECOSYSTEM
TABLE 15 AVERAGE SELLING PRICE TREND OF PEDIATRIC VACCINES, BY KEY PLAYER, 2024–2026 (USD)
TABLE 16 AVERAGE SELLING PRICE TREND OF ADULT VACCINES, BY KEY PLAYER, 2024–2026 (USD)
TABLE 17 AVERAGE SELLING PRICE TREND OF VACCINES, BY REGION, 2022–2024 (USD)
TABLE 18 IMPORT DATA FOR HS CODE 300220, 2021–2025 (USD THOUSAND)
TABLE 19 IMPORT DATA FOR HS CODE 300220, 2021–2025 (TONS)
TABLE 20 EXPORT DATA FOR HS CODE 300220, 2021–2025 (USD THOUSAND)
TABLE 21 EXPORT DATA FOR HS CODE 300220, 2021–2025 (TONS)
TABLE 22 VACCINES MARKET: KEY CONFERENCES AND EVENTS, 2026–2027
TABLE 23 US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 24 NUMBER OF VACCINES DELIVERED BY UNICEF, 2024–2026
TABLE 25 WHO VACCINE PURCHASE DATABASE, BY PROCUREMENT MECHANISM, 2022–2024
TABLE 26 WHO VACCINE PURCHASE DATABASE, BY MANUFACTURER, 2022–2024
TABLE 27 WHO VACCINE PURCHASE DATABASE, BY INDICATION, 2022–2024
TABLE 28 WHO VACCINE PURCHASE DATABASE, BY REGION, 2022–2024
TABLE 29 VACCINE PRODUCTION CAPACITY, BY KEY PLAYER, 2025
TABLE 30 KEY VACCINE MANUFACTURING CAPACITY EXPANSIONS, 2025–2026
TABLE 31 VACCINES MARKET: INDICATIVE LIST OF PATENTS, 2026
TABLE 32 CASE STUDIES OF AI IMPLEMENTATION IN VACCINES MARKET
TABLE 33 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN VACCINES
TABLE 34 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 35 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 36 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 37 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 38 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY VACCINES
TABLE 39 KEY BUYING CRITERIA, BY END USER
TABLE 40 VACCINES MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
TABLE 41 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES
TABLE 42 PNEUMOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 43 NORTH AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 44 EUROPE: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45 ASIA PACIFIC: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46 LATIN AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES
TABLE 48 INFLUENZA VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 49 NORTH AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 EUROPE: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51 ASIA PACIFIC: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 LATIN AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES
TABLE 54 HPV VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 55 NORTH AMERICA: HPV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56 EUROPE: HPV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 ASIA PACIFIC: HPV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58 LATIN AMERICA: HPV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 LIST OF COMMERCIALLY AVAILABLE HERPES ZOSTER VACCINES
TABLE 60 HERPES ZOSTER VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 NORTH AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 EUROPE: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 ASIA PACIFIC: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64 LATIN AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES
TABLE 66 COMBINATION VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 67 NORTH AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 EUROPE: COMBINATION VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 69 ASIA PACIFIC: COMBINATION VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 LATIN AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES
TABLE 72 MENINGOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 73 NORTH AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74 EUROPE: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 ASIA PACIFIC: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 LATIN AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES
TABLE 78 ROTAVIRUS VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 79 NORTH AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 EUROPE: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81 ASIA PACIFIC: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 LATIN AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 LIST OF COMMERCIALLY AVAILABLE RSV VACCINES
TABLE 84 RSV VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 85 NORTH AMERICA: RSV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 EUROPE: RSV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87 ASIA PACIFIC: RSV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 LATIN AMERICA: RSV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES
TABLE 90 DTP VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 91 NORTH AMERICA: DTP VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 EUROPE: DTP VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 ASIA PACIFIC: DTP VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 LATIN AMERICA: DTP VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES
TABLE 96 HEPATITIS VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 97 NORTH AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 EUROPE: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 ASIA PACIFIC: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 LATIN AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES
TABLE 102 VARICELLA VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 103 NORTH AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 EUROPE: VARICELLA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105 ASIA PACIFIC: VARICELLA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 LATIN AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 TOP 10 COUNTRIES WITH MEASLES OUTBREAKS, JANUARY 2025–JULY 2025
TABLE 108 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES
TABLE 109 MMR VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 110 NORTH AMERICA: MMR VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 EUROPE: MMR VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112 ASIA PACIFIC: MMR VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 LATIN AMERICA: MMR VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 POLIO VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 115 NORTH AMERICA: POLIO VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116 EUROPE: POLIO VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117 ASIA PACIFIC: POLIO VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 LATIN AMERICA: POLIO VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 COVID-19 VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 120 NORTH AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121 EUROPE: COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 ASIA PACIFIC: COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 LATIN AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS
TABLE 125 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 126 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 127 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 131 EXAMPLES OF RECOMBINANT VACCINES
TABLE 132 RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 133 NORTH AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134 EUROPE: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 ASIA PACIFIC: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 LATIN AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 EXAMPLES OF CONJUGATE VACCINES
TABLE 138 CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 139 NORTH AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140 EUROPE: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 ASIA PACIFIC: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142 LATIN AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES
TABLE 144 INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 145 NORTH AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 EUROPE: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147 ASIA PACIFIC: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 LATIN AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 149 EXAMPLES OF LIVE ATTENUATED VACCINES
TABLE 150 LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 151 NORTH AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 EUROPE: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 ASIA PACIFIC: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154 LATIN AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 EXAMPLES OF TOXOID VACCINES
TABLE 156 TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 157 NORTH AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158 EUROPE: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159 ASIA PACIFIC: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160 LATIN AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 162 NORTH AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 163 EUROPE: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 ASIA PACIFIC: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 LATIN AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 COVID-19 VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 167 MRNA COVID-19 VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 168 NORTH AMERICA: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 EUROPE: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 ASIA PACIFIC: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 171 LATIN AMERICA: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 VIRAL VECTOR COVID-19 VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 173 NORTH AMERICA: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174 EUROPE: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 ASIA PACIFIC: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 LATIN AMERICA: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 OTHER COVID-19 VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 178 NORTH AMERICA: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179 EUROPE: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 180 ASIA PACIFIC: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 LATIN AMERICA: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION)
TABLE 183 EXAMPLES OF MULTIVALENT VACCINES
TABLE 184 MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 185 NORTH AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 EUROPE: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 ASIA PACIFIC: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 LATIN AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 EXAMPLES OF MONOVALENT VACCINES
TABLE 190 MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 191 NORTH AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 192 EUROPE: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 ASIA PACIFIC: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 LATIN AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 196 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION
TABLE 197 VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 198 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 203 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 208 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION)
TABLE 213 ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION)
TABLE 214 NORTH AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 215 EUROPE: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION)
LIST OF FIGURES
FIGURE 1 VACCINES MARKET SEGMENTATION & REGIONS COVERED
FIGURE 2 MARKET SCENARIO
FIGURE 3 GLOBAL VACCINES MARKET (INCLUDING COVID-19 VACCINES), 2024–2031
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN VACCINES MARKET, 2023–2026
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF VACCINES MARKET
FIGURE 6 HIGH-GROWTH SEGMENTS IN VACCINES MARKET (EXCLUDING COVID-19 VACCINES), 2026–2031
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN VACCINES MARKET (EXCLUDING COVID-19 VACCINES), IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 8 FOCUS ON VACCINE DEVELOPMENT AND LAUNCHES TO DRIVE MARKET GROWTH
FIGURE 9 US AND MULTIVALENT VACCINES ACCOUNTED FOR THE LARGEST SHARE OF THE VACCINES MARKET IN NORTH AMERICA IN 2025
FIGURE 10 ASIA PACIFIC IS LIKELY TO BE FASTEST-GROWING MARKET DURING 2026–2031
FIGURE 11 INTRAMUSCULAR AND SUBCUTANEOUS ROUTE TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 12 VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 13 US: NOVEL INFLUENZA A VIRUS CASES, BY SEASON (2010–2011 TO 2025–2026 SEASON)
FIGURE 14 MANUFACTURING-RELATED PARAMETERS INCLUDED IN COST MODEL
FIGURE 15 US: ESTIMATED NUMBER OF NEW CANCER CASES AND DEATHS BY SITE, 2025
FIGURE 16 VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 17 GLOBAL GDP GROWTH, 2020–2030
FIGURE 18 VACCINES MARKET: VALUE CHAIN ANALYSIS
FIGURE 19 VACCINES MARKET: CLINICAL TRIALS, BY PHASE
FIGURE 20 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION
FIGURE 21 VACCINES MARKET ECOSYSTEM
FIGURE 22 AVERAGE SELLING PRICE TREND OF VACCINES, BY DISEASE INDICATION, 2024–2026 (USD)
FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN VACCINES MARKET
FIGURE 24 VACCINES MARKET: PHARMACEUTICAL M&A DEAL ACTIVITY, NUMBER, AND AGGREGATE TOTAL VALUE, 2021–2025
FIGURE 25 TOP APPLICANTS/OWNERS (COMPANIES) FOR VACCINE PATENTS, 2015–2025
FIGURE 26 IMPACT OF AI/GEN AI ON VACCINES MARKET
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES
FIGURE 28 KEY BUYING CRITERIA, BY END USER
FIGURE 29 NORTH AMERICA: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
FIGURE 30 ASIA PACIFIC: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
FIGURE 31 REVENUE ANALYSIS OF KEY PLAYERS IN VACCINES MARKET, 2021–2025 (USD BILLION)
FIGURE 32 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VACCINES MARKET, 2025
FIGURE 33 VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 34 VACCINES MARKET: COMPANY FOOTPRINT
FIGURE 35 VACCINES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 36 EV/EBITDA OF KEY VENDORS
FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 38 VACCINES MARKET: PRODUCT COMPARATIVE ANALYSIS
FIGURE 39 PFIZER INC.: COMPANY SNAPSHOT (2025)
FIGURE 40 GSK PLC: COMPANY SNAPSHOT (2025)
FIGURE 41 MERCK & CO., INC.: COMPANY SNAPSHOT (2025)
FIGURE 42 SANOFI: COMPANY SNAPSHOT (2025)
FIGURE 43 CSL: COMPANY SNAPSHOT (2025)
FIGURE 44 EMERGENT: COMPANY SNAPSHOT (2025)
FIGURE 45 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 46 ASTRAZENECA: COMPANY SNAPSHOT (2025)
FIGURE 47 BAVARIAN NORDIC: COMPANY SNAPSHOT (2025)
FIGURE 48 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2025)
FIGURE 49 PANACEA BIOTEC: COMPANY SNAPSHOT (2024)
FIGURE 50 NOVAVAX: COMPANY SNAPSHOT (2025)
FIGURE 51 INOVIO PHARMACEUTICALS: COMPANY SNAPSHOT (2025)
FIGURE 52 VACCINES MARKET: RESEARCH DESIGN
FIGURE 53 VACCINES MARKET: BREAKDOWN OF PRIMARIES
FIGURE 54 GLOBAL VACCINES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
FIGURE 55 GLOBAL VACCINES MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2025
FIGURE 56 ILLUSTRATIVE EXAMPLE OF PFIZER INC.: REVENUE ANALYSIS, 2025
FIGURE 57 VACCINES MARKET: INSIGHTS FROM PRIMARIES
FIGURE 58 ILLUSTRATIVE EXAMPLE OF INFLUENZA VACCINES: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2025
FIGURE 59 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 60 VACCINES MARKET: CAGR PROJECTIONS
FIGURE 61 VACCINES MARKET: DATA TRIANGULATION
FIGURE 1 VACCINES MARKET SEGMENTATION & REGIONS COVERED
FIGURE 2 MARKET SCENARIO
FIGURE 3 GLOBAL VACCINES MARKET (INCLUDING COVID-19 VACCINES), 2024–2031
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN VACCINES MARKET, 2023–2026
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF VACCINES MARKET
FIGURE 6 HIGH-GROWTH SEGMENTS IN VACCINES MARKET (EXCLUDING COVID-19 VACCINES), 2026–2031
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN VACCINES MARKET (EXCLUDING COVID-19 VACCINES), IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 8 FOCUS ON VACCINE DEVELOPMENT AND LAUNCHES TO DRIVE MARKET GROWTH
FIGURE 9 US AND MULTIVALENT VACCINES ACCOUNTED FOR THE LARGEST SHARE OF THE VACCINES MARKET IN NORTH AMERICA IN 2025
FIGURE 10 ASIA PACIFIC IS LIKELY TO BE FASTEST-GROWING MARKET DURING 2026–2031
FIGURE 11 INTRAMUSCULAR AND SUBCUTANEOUS ROUTE TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 12 VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 13 US: NOVEL INFLUENZA A VIRUS CASES, BY SEASON (2010–2011 TO 2025–2026 SEASON)
FIGURE 14 MANUFACTURING-RELATED PARAMETERS INCLUDED IN COST MODEL
FIGURE 15 US: ESTIMATED NUMBER OF NEW CANCER CASES AND DEATHS BY SITE, 2025
FIGURE 16 VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 17 GLOBAL GDP GROWTH, 2020–2030
FIGURE 18 VACCINES MARKET: VALUE CHAIN ANALYSIS
FIGURE 19 VACCINES MARKET: CLINICAL TRIALS, BY PHASE
FIGURE 20 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION
FIGURE 21 VACCINES MARKET ECOSYSTEM
FIGURE 22 AVERAGE SELLING PRICE TREND OF VACCINES, BY DISEASE INDICATION, 2024–2026 (USD)
FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN VACCINES MARKET
FIGURE 24 VACCINES MARKET: PHARMACEUTICAL M&A DEAL ACTIVITY, NUMBER, AND AGGREGATE TOTAL VALUE, 2021–2025
FIGURE 25 TOP APPLICANTS/OWNERS (COMPANIES) FOR VACCINE PATENTS, 2015–2025
FIGURE 26 IMPACT OF AI/GEN AI ON VACCINES MARKET
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES
FIGURE 28 KEY BUYING CRITERIA, BY END USER
FIGURE 29 NORTH AMERICA: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
FIGURE 30 ASIA PACIFIC: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
FIGURE 31 REVENUE ANALYSIS OF KEY PLAYERS IN VACCINES MARKET, 2021–2025 (USD BILLION)
FIGURE 32 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VACCINES MARKET, 2025
FIGURE 33 VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 34 VACCINES MARKET: COMPANY FOOTPRINT
FIGURE 35 VACCINES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 36 EV/EBITDA OF KEY VENDORS
FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 38 VACCINES MARKET: PRODUCT COMPARATIVE ANALYSIS
FIGURE 39 PFIZER INC.: COMPANY SNAPSHOT (2025)
FIGURE 40 GSK PLC: COMPANY SNAPSHOT (2025)
FIGURE 41 MERCK & CO., INC.: COMPANY SNAPSHOT (2025)
FIGURE 42 SANOFI: COMPANY SNAPSHOT (2025)
FIGURE 43 CSL: COMPANY SNAPSHOT (2025)
FIGURE 44 EMERGENT: COMPANY SNAPSHOT (2025)
FIGURE 45 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 46 ASTRAZENECA: COMPANY SNAPSHOT (2025)
FIGURE 47 BAVARIAN NORDIC: COMPANY SNAPSHOT (2025)
FIGURE 48 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2025)
FIGURE 49 PANACEA BIOTEC: COMPANY SNAPSHOT (2024)
FIGURE 50 NOVAVAX: COMPANY SNAPSHOT (2025)
FIGURE 51 INOVIO PHARMACEUTICALS: COMPANY SNAPSHOT (2025)
FIGURE 52 VACCINES MARKET: RESEARCH DESIGN
FIGURE 53 VACCINES MARKET: BREAKDOWN OF PRIMARIES
FIGURE 54 GLOBAL VACCINES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
FIGURE 55 GLOBAL VACCINES MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2025
FIGURE 56 ILLUSTRATIVE EXAMPLE OF PFIZER INC.: REVENUE ANALYSIS, 2025
FIGURE 57 VACCINES MARKET: INSIGHTS FROM PRIMARIES
FIGURE 58 ILLUSTRATIVE EXAMPLE OF INFLUENZA VACCINES: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2025
FIGURE 59 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 60 VACCINES MARKET: CAGR PROJECTIONS
FIGURE 61 VACCINES MARKET: DATA TRIANGULATION
